Bacterial and viral superantigens: roles in autoimmunity?

Hans Acha-Orbea

Abstract
Superantigens are bacterial, viral, or retroviral proteins which can activate specifically a large proportion of T cells. In contrast with classical peptide antigen recognition, superantigens do not require processing to small peptides but act as complete or partially processed proteins. They can bind to major histocompatibility complex class II molecules and stimulate T cells expressing particular T cell receptor Vβ chains. The other polymorphic parts of the T cell receptor, which are crucial for classical antigen recognition, are not important for this interaction. When this strategy is used a large proportion of the host immune system can be activated shortly after infection. The activated cells have a wide variety of antigen specificities. The ability to stimulate polyclonal B (IgG) as well as T cell responses raises possibilities of a role for superantigens in the induction of autoimmune diseases. Superantigens have been a great tool in the hands of immunologists in unravelling some of the basic mechanisms of tolerance and immunity.

(Ann Rheum Dis 1993; 52: S6–S16)

Classical antigen recognition by T cells occurs by interaction of self major histocompatibility complex (MHC) proteins, which bind small fragments of proteins, with T cell receptor (TCR). These three components are briefly described below. More detailed information can be found in excellent reviews and the references therein.

The MHC encodes many different proteins. Among these the MHC class I and class II molecules are important in this context. These dimeric molecules are highly polymorphic in the population. Of the order of 50 alleles have been defined for the different MHC class I and class II molecules. The major function of these molecules is the presentation of antigens to the T cells by acting as receptors able to bind thousands of 8–9 (MHC class I) or 9–16 (MHC class II) amino acid long processed peptides. Such peptides are generated from proteins in the cytoplasm (for MHC class I presentation) or in endosomes (for MHC class II presentation) by specialised proteases. Most of the antigens entering the cell from the outside will be associated with MHC class II molecules, whereas proteins produced within the cell are presented by MHC class I molecules. Despite the high numbers of peptides which can be bound to a particular MHC molecule, these receptors show striking specificity for peptides they bind. This specificity is due to differences in the amino acid sequence in the N-terminal part of MHC molecules which forms the peptide binding pocket that can accommodate two to four amino acids of the peptide. Specific amino acids could be implicated at specific localisations in the bound peptides for several different MHC class I as well as class II molecules. Different MHC class I and class II proteins bind different sets of peptides. Single amino acid differences in this peptide binding region can heavily influence the peptides which can bind to a particular MHC class I or class II molecule.

The formation of a trimolecular complex between MHC, peptide, and TCR is highly specific in that a particular TCR can interact only with specific MHC molecules which have bound a particular peptide. For this interaction TCR and MHC sequences as well as peptide sequences are important. As recognition occurs almost exclusively with self MHC molecules, and the same peptides cannot be presented in the context of another MHC molecule, it is called MHC restricted. This MHC restricted antigen recognition by T lymphocytes leads to formation of a trimolecular complex between short antigenic peptides bound to MHC molecules and recognition by a TCR (fig 1A).

In addition to these molecules, a series of other receptors and coreceptors intensify this interaction. Most of these intensifying molecules do not contribute to the specificity of the interaction and are not discussed here. One pair of these coreceptors intensifies the interaction of the TCR with MHC class I molecules (CD8) or MHC class II molecules (CD4). Cytotoxic T cells are found amongst the former, and helper T cells amongst the latter.

The TCR is the end product of a series of recombination events during the maturation and differentiation of T cells. This brings together the constant region which is shared between all the receptor molecules with the two or three highly polymorphic parts: variable (V), diversity (D) (in the case of the β chain only), and junctional (J) elements. These elements are encoded as V and J clusters, separated but in the same chromosomal localisation as the constant region. In addition, a tremendous heterogeneity is introduced by...
Bacterial and viral superantigens

Figure 1. Classical peptide and superantigen recognition. (A) In classical antigen recognition a processed peptide is presented by major histocompatibility complex (MHC) class I or class II molecules to the T cell receptor (TCR). The CD4 or CD8 molecule intensifies this interaction. (B) In superantigen recognition the superantigen crosslinks the TCR Vβ with MHC class II. It is not known whether antigenic peptides are bound to MHC and whether CD4 and CD8 are of importance.

random introduction and deletion of short sequences in the V-D, V-J, and D-J regions during this recombination process. The functional TCR is composed of an α and a β chain (which are encoded on different chromosomes and use different elements), and, as only one type of TCR molecule is expressed on one T cell clone, is responsible for giving the T cell the high specific recognition capability. In mice there are about 25 Vβ, 12 Jβ, 75 Vα, and 75 Jα elements encoded. With the introduced random sequences of the order of 10^13 different TCR molecules can theoretically be produced, by far exceeding the potential repertoire of a single mouse. In humans about 100 Vβ elements exist, whereas the other TCR elements are similar in number in mice and humans. In humans the Vα families, which are defined by 70% amino acid homology, are much larger than in the mouse. The number of families is comparable. In a classical MHC restricted peptide specific T cell response about one in 100,000 T cells can interact with one particular immunogenic peptide-self MHC complex with significant affinity.

Biology of superantigens

The term superantigen has been given to antigens which can activate of the order of one in 10 T cells, allowing the activation of about 10,000 times more T lymphocytes with a single antigen than in classical MHC-peptide recognition.7-12 In contrast with T cell mitogens, superantigens have a high degree of specificity.

It became clear recently that superantigens have a new way of interaction with MHC molecules and the TCR. Instead of interacting with the most polymorphic part of the receptor, they recognise one or several different TCR Vβ regions which make only a small contribution to the overall heterogeneity.13-18 They can interact with MHC molecules and cross link the TCR to form an aberrant trimolecular complex (fig 1B). Neither the TCR nor the trimolecular complex has yet been crystallised, but structural homology with previously crystallised structures allows us to suggest a tentative structure.14 These superantigens are not processed to small peptides like the classical antigens but function as entire molecules19-21 (or possibly partially cleaved molecules in the case of retroviral superantigens, see below). Based on the analysis of MHC class II and TCR mutants which lost or gained superantigen binding, as well as the recent crystallisation and mutagenesis analysis on the bacterial superantigen staphylococcal enterotoxin B, it is now thought that superantigens cross link the TCR with MHC class II molecules on the lateral side of the complex (fig 1B).9-11 21-30

Recently, with the help of superantigens and transgenic mice, direct evidence for two basic tolerance mechanisms (clonal deletion of self reactive cells in the thymus13 14 31-36 and induction of unresponsiveness (anergy) in the periphery37 38) was produced. In this review only the results obtained with superantigens are discussed.

T cells mature in the thymus, where they learn to distinguish between self and foreign. Early in life the immune system is plastic and can adapt to learn what belongs to self and what is foreign. The thymus plays an important part in this decision. Cells which are strongly self reactive are negatively selected (deleted), whereas T cells which can interact weakly with self MHC molecules are positively selected for export into the periphery33 39-41. Owing to positive selection the cells are trained to recognise antigens bound to self MHC molecules, as otherwise a large percentage of T cells which cannot interact with self MHC molecules would be wasted. Negative selection in the thymus (deletion) of ‘self reactive’ T cells has been found in mice expressing superantigens at birth.17 12-16 42 With the help of monoclonal antibodies specific for Vβ regions of the TCR an almost complete elimination of the superantigen reactive Vβ-bearing T cells has been noted in mature thymocytes as well as in the peripheral T cell repertoire.

A first encounter with a superantigen in an adult mouse in vivo leads to an initial expansion of the reactive T cells bearing
one or several specific TCR \( V_\beta \) regions.\(^7\) Shortly after this encounter the T cells become unresponsive (anergic).\(^8\) In the case of anergy the cells are still present but have lost the ability to respond a second time to the same antigen; this is in striking contrast with a second challenge with a conventional antigen where a secondary response is more intense. One of the important findings is that these anergic T cells lose the ability to produce one of the important lymphokines for T cell survival and division—namely, interleukin 2.\(^9\) In some but not all cases this state of anergy can be reversed by addition of exogenous interleukin 2. With the availability of monoclonal antibodies specific for TCR \( V_\beta \) and \( V_\alpha \) regions it became easy to measure these changes in the frequencies of the responding T cells. As they make up about 10% of the total mouse T cell repertoire they can easily be followed. Negative selection in the thymus can eliminate 90–99% of T cells expressing a TCR \( V_\beta \) element that can interact with a particular superantigen.

Negative selection in the thymus can also be induced with an exogenous antigen, such as a bacterial superantigen injected at birth.\(^7\) Normally, however, negative selection in the thymus (as well as tolerance) is only maintained if the antigen is present continuously and will fade out with the disappearance of the antigen. For longlasting tolerance the antigen has to be present continuously, as in the case of retroviral infection (see below).

**Nature of superantigens**

Superantigens have been found in different infectious agents. The recently described superantigens originate from bacteria (staphylococci, \(^9\) \(^11\) \(^44\) \(^45\) \(^-\) \(^52\) streptococci, \(^53\) \(^145\) \(^147\) mycoplasma, \(^54\) \(^148\) \(^149\) yersinia),\(^55\) retroviruses (mouse mammary tumour virus (MMTV), \(^9\) \(^56\) \(^66\) possibly, human immunodeficiency virus (HIV), \(^67\) \(^68\) possibly, murine leukaemia virus\(^69\) ), and other viruses (rabies virus\(^70\) ). The exclusive distribution of these molecules in microbes raises the question of how important the expression of these structures is for microbes. Probably, the strategy of activation of the host immune response leads to an overstimulation of the immune system which allows the pathogens more efficient infection.\(^71\) \(^72\) Up to now, however, only few results show such an advantage directly.

**Bacterial superantigens**

Overall, the described bacterial superantigens are of similar size (20–30 kilodaltons) with high to very low amino acid sequence homology (20–80%) (for review see ref 11). Most likely many of them developed by convergent evolution towards the same aim. These bacterial superantigens have been shown to interact strongly with MHC class II but not MHC class I molecules.\(^9\) \(^19\) \(^21\) \(^73\) \(^74\) Their affinities are of the same order of magnitude as the binding affinities of antibodies to their antigen \(10^{-5} \sim 10^{-9}\) M. They can bind to mouse, rat and human MHC class II antigens. Moreover, for T cell stimulation to occur, class II expressing cells are required. Table 1 provides a summary of the differences between superantigen and classical peptide recognition. Normally, T cells expressing the surface marker CD4 (amongst which helper T cells are found) react with antigens presented by MHC class II molecules, whereas cells expressing CD8 (which include cytotoxic T cells) react with antigens presented by MHC class I molecules. Bacterial superantigens, however, break this rule; both T cell subpopulations are easily stimulated by MHC class II expressing cells in the presence of bacterial superantigens.\(^74\) In addition, no MHC restriction is seen. For example, mouse superantigen presenting cells can stimulate human T cells. The only requirement is MHC class II expression of the presenting cell and expression of a specific TCR \( V_\beta \) chain by the T cell.

Different MHC class II isotypes have different affinities for various bacterial superantigens.\(^9\) \(^20\) \(^-\) \(^21\) \(^73\) In general, they interact better with human than mouse MHC class II proteins. Superantigens are the most potent T cell mitogens known. Their affinity constants are in the picomolar to nanomolar range. Table 2 lists the currently known bacterial superantigens and their TCR \( V_\beta \) specificities in mice and humans. In mice many more TCR \( V_\beta \) specific monoclonal antibodies are available, which makes it much easier to define these specificities. Therefore the TCR specificities of bacterial superantigens in mice are more completely documented than in humans.

One of these superantigens, staphylococcal enterotoxin B (SEB), has recently been crystallised.\(^30\) In addition, introduction of mutations in the SEB coding sequence allows localisation of the MHC and the TCR interaction residues.\(^79\) For all the analysed superantigens the affinity for the TCR seems to be much lower than for MHC molecules. In addition to contact residues on the superantigen, amino acid contact residues on the TCR and the MHC class II molecules have been characterised for both retroviral (see below) and bacterial superantigens.\(^31\) \(^29\)

The overall conclusions of these studies suggest that unprocessed superantigen molecules can interact with the lateral side of the TCR and the MHC class II molecules (see fig 1B).

As described above, injection of bacterial superantigens into newborn mice leads to thymic clonal deletion of the reactive T cells.\(^7\) Injection into adult mice leads to an expansion of the reactive T cells, which thereafter leads to induction of non-responsiveness (anergy).\(^48\) \(^49\) For a limited time period the T cells expressing the responsive TCR \( V_\beta \) are reduced in number in vivo. Anergy can also be induced in T cell clones with bacterial superantigens.\(^75\) A recent report showed that injection of
superantigens can lead to a profound inhibition of conventional antigen responses. It is still not clear, however, whether it is this effect that forced bacteria to develop superantigens.

Well known effects of superantigens include food poisoning after ingestion of staphylococcal exotoxins, the toxic shock syndrome, arthritis after mycoplasma infections, possibly Kawasaki disease, and possibly rheumatoid fever after streptococcal infections (see below). Table 3 lists the diseases and the causing superantigens.

Retroviral superantigens in mice

In mice, genes have been mapped which encode endogenous superantigens. They were originally described as minor lymphocyte stimulating (Mls) antigens by Festenstein some 20 years ago. He discovered that a large proportion of cells responsive to Mls antigens are stimulated in an MHC non-restricted fashion when T cells from mice lacking a particular Mls antigen, such as Mls-1*, are mixed with B cells expressing the Mls-1* antigen. It was clear that the genes encoding these proteins are dominant and, surprisingly, always have an Mls allele and a null allele which are unable to stimulate such a vigorous T cell response.

Many such biallelic systems have been defined in laboratory mouse strains and map different chromosomal localisations. It was discovered later that the T cells reacting with Mls antigens share expression of particular TCR V\(_{\beta}\) chains. Mice expressing such an Mls gene delete most of the T cells expressing the responsive TCR V\(_{\beta}\) chain during thymic maturation.

After an intensive search for over 20 years it became clear recently that these Mls antigens are encoded by endogenous proviruses of the MMTV family. Figure 2 shows the typical buildup of such a virus. In the 3' long terminal repeat, an open reading frame (ORF) was found which represented a puzzle to retrovirologists. They had difficulties ascribing a function to this potential protein, which was never found in normal or tumour cells. It was thought that this protein had an effect on gene regulation and both positive and negative gene regulation were described. It turned out that it is this protein which represents a superantigen. As viral genes often have more than one function it will be interesting to see if other functions can be

**Table 1** Characteristics of superantigens

<table>
<thead>
<tr>
<th>Origin</th>
<th>Protein</th>
<th>Superantigen</th>
</tr>
</thead>
<tbody>
<tr>
<td>Processing</td>
<td>Yes (small peptides)</td>
<td>Bacterial</td>
</tr>
<tr>
<td>Presentation</td>
<td>MHC* class I, or class II MHC restricted</td>
<td>Viral</td>
</tr>
<tr>
<td>Frequency of responding cells</td>
<td>1 in 10^4 to 10^5</td>
<td>Partial or no</td>
</tr>
<tr>
<td>TCR* elements</td>
<td></td>
<td>MHC class II on B cells, not</td>
</tr>
<tr>
<td>V(<em>{\alpha}) &amp; V(</em>{\beta})</td>
<td></td>
<td>MHC restricted</td>
</tr>
</tbody>
</table>

*| MHC=major histocompatibility complex; TCR=T cell receptor.

**Table 2** Bacterial superantigens

<table>
<thead>
<tr>
<th>TCR*V(_{\beta})</th>
<th>In humans</th>
<th>In mice</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>3</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>4</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>5</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>6</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>7</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>8</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>9</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>10</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>11</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>12</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>13</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>14</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>15</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>16</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>17</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>18</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>19</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Note that the most homologous TCR V\(_{\beta}\) elements do not have the same numbers in mice and humans. The molecular structures of Yersinia enterocolitica, Mycoplasma arthritidis superantigens have not yet been characterized.

*TCR=T cell receptor; TSST-1=toxic shock syndrome toxin; SEA, SEB, SEC, SED, SEE=staphylococcal enterotoxin A, B, C, D, E; MAM=Mycoplasma arthritidis superantigen.

**Table 3** Bacterial superantigens and disease

<table>
<thead>
<tr>
<th>Superantigen</th>
<th>Disease</th>
</tr>
</thead>
<tbody>
<tr>
<td>Staphylococcal enterotoxins</td>
<td>Food poisoning, shock</td>
</tr>
<tr>
<td>Staphylococcal TSST-1*</td>
<td>Toxic shock syndrome</td>
</tr>
<tr>
<td>Mycoplasma arthritidis superantigen (MAS)</td>
<td>Arthritis, shock</td>
</tr>
<tr>
<td>Streptococcal superantigen: M protein, pyrogenic exotoxins</td>
<td>Rheumatic fever, shock, scarlet fever</td>
</tr>
</tbody>
</table>

*TSST-1=toxic shock syndrome toxin.
found for this ORF. Most laboratory as well as wild mice have two to 10 copies of different MMTV proviruses integrated into their genome.10 The different MMTVs are about 95% homologous in their amino acid sequence. Table 4 lists the currently known endogenous MMTVs and their TCR V_{8} specificities.

When ORF molecules interacting with the different TCR V_{8} elements are aligned a striking correlation between the C-terminal amino acid sequence and the TCR V_{8} specificity is observed.9 19 60 86 At present some 15 ORF sequences are known and in all cases a striking correlation between C-terminal sequence and TCR V_{8} specificity exists. The last 10–30 amino acids seem to determine the V_{8} specificity. Figure 2 shows the presumed structure of an ORF molecule.

These endogenous superantigens also lead to thymic deletion of the reactive cells when encountered at birth. Thymic deletion can also be induced after injection of cells bearing a superantigen into adult mice.60 As described above for bacterial superantigens, immune stimulation of the reactive T cells occurs when the first encounter happens in adult life followed by induction of unresponsiveness (anergy). Whether the loss of the reactive T cells after this initial stimulation is due to peripheral deletion or to dilution of the cells which can no longer divide is not clear at the moment.

These endogenous superantigens originate from infectious viruses which are still found in wild and laboratory mice (for reviews on MMTV see refs 102, 106–110). In contrast with endogenous transmission, which follows the principles of mendelian inheritance, infectious viruses are transmitted through milk from mother to offspring. The following scenario for infection has been suggested by experiments in newborn or adult mice: the virus is taken up through milk from birth and contacts lymphocytes in the Peyer's patches (Karapetian O, Shakhov A N, Kraehenbuhl J P, et al, unpublished data). As soon as the immune system matures sufficiently (around two to three days after birth), infection of B cells is followed by superantigen (ORF) mediated T-B interaction with T cells expressing the responsive TCR V_{8} elements.86 111 A strong augmentation of the infected B cells which express the superantigen occurs111; at the same time a continuous stimulation (which would be harmful for the host) is prevented by anergisation of the responsive T cells. The superantigen expression allows about 1000 times more efficient infection (Held W, Waanders G A, Shakhov A N et al, unpublished data). We have recently shown that the virus infects lymphocytes exclusively in Peyer’s patches and the lymph nodes of the small intestine (Karapetian O, Shakhov A N, Kraehenbuhl J P, et al, unpublished data). The infection of lymphocytes represents a crucial step in the life cycle of the virus. Mice lacking responsive T cells or mice with a defective immune system cannot propagate the virus efficiently.112 Later in life the virus jumps from lymphocytes to the mammary gland epithelium where large scale virus production occurs which is secreted into the milk. This is the only place where free virus particles have been found. When the mothers transmit the virus to their offspring the vicious circle is closed. Figure 3 shows a typical life cycle of MMTV.

As the name implies, these viruses are the major causative agent of mammary tumours in mice. Integration close to a mouse proto-oncogene can activate it and induce the first steps towards carcinogenesis.113 114 This virus has very cleverly profited from the weaknesses of the mouse’s immune system. In doing so it has given us tools which can help us to understand better its normal function. The finding of an ‘infectious superantigen’ (MMTV), especially, allows experiments which help towards understanding the immune system, the retroviral life cycle, and the interplay between the two.64 86 111 115 These experiments are still in progress. One important point for this discussion is the effect on B cells after local infection of adult mice with MMTV. Adult mice cannot eliminate MMTV; they remain infected for the rest of
Table 4 Retroviral superantigens

<table>
<thead>
<tr>
<th>Mouse</th>
<th>Human</th>
<th>Retroviral superantigen</th>
<th>References</th>
</tr>
</thead>
<tbody>
<tr>
<td>3</td>
<td>?</td>
<td>Mtv-1, -3, -6, -13, -44, -MAI</td>
<td>58,59,63,138-140</td>
</tr>
<tr>
<td>5</td>
<td>?</td>
<td>Mtv-6, MuLV?</td>
<td>57,69</td>
</tr>
<tr>
<td>5-1</td>
<td>?</td>
<td>Mtv-8, -9</td>
<td>56-58</td>
</tr>
<tr>
<td>5-2</td>
<td>?</td>
<td>Mtv-8, -9</td>
<td>56-58</td>
</tr>
<tr>
<td>6</td>
<td>12</td>
<td>Mtv-7, -43, -44, -SW, MMTV(SW)</td>
<td>Shakhov and Acha-Orbea, in preparation</td>
</tr>
<tr>
<td>7</td>
<td>?</td>
<td>Mtv-7, -29, -43, -SW, -29, MMTV(SW)</td>
<td>59,63,87,141, Shakhov and Acha-Orbea, in preparation</td>
</tr>
<tr>
<td>8-1</td>
<td>?</td>
<td>Mtv-7, -43, -SW, MMTV(SW)</td>
<td>59,63,87,141, Shakhov and Acha-Orbea, in preparation</td>
</tr>
<tr>
<td>11</td>
<td>?</td>
<td>Mtv-8, -9, -11</td>
<td>62</td>
</tr>
<tr>
<td>12</td>
<td>?</td>
<td>Mtv-8, -9, -11</td>
<td>97-99</td>
</tr>
<tr>
<td>14</td>
<td>?</td>
<td>Mtv-2, MMTV(GR), MMTV(C3H)</td>
<td>27,59,144</td>
</tr>
<tr>
<td>15</td>
<td>?</td>
<td>Mtv-2, MMTV(GR), MMTV(C3H)</td>
<td>27</td>
</tr>
<tr>
<td>16</td>
<td>?</td>
<td>Mtv-?</td>
<td>97-99,143</td>
</tr>
<tr>
<td>17</td>
<td>?</td>
<td>f Mtv-3, -9, -9</td>
<td></td>
</tr>
<tr>
<td>19</td>
<td>?</td>
<td>f Mtv-6, -MAI</td>
<td>140,154</td>
</tr>
<tr>
<td>20</td>
<td>?</td>
<td>New Mtv?</td>
<td>Hodes, personal communication</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Mtv-3</td>
<td>65</td>
</tr>
</tbody>
</table>

Note that the most homologous TCR V8 elements do not have the same numbers in mice and humans. Mtv-n stands for integrated proviruses, MMTV stands for infectious viruses. Most human TCR V8-MMTV ORF interactions have not yet been measured.

TCR= T cell receptor; MMTV=mouse mammary tumour virus; ORF=open reading frame.

There are still gaps in our knowledge about the interplay between virus and host, but so far (and surely even more so in the near future) retroviral and bacterial superantigens have been great tools in the hands of immunologists, allowing consideration of questions about the normal immune response as well as retrovirology. Table 5 compares current knowledge on bacterial and retroviral superantigens.

Human viral superantigens

During the last year two reports suggested that HIV may encode a superantigen.67,68 The first analysed the expression of mRNA of the different TCR V8 elements in the peripheral blood of patients at late stages of AIDS. Several TCR V8 elements were found to be reduced strongly in patients with late stage disease, after the drop in the CD4+ T cell population. A semiquantitative polymerase chain reaction was used to measure mRNA expression in unseparated blood isolates.67 Analyses on purified CD4+ T cell populations are required to consider this question more directly as, possibly, the V8 elements which were reduced are underrepresented in the CD8+ T cell population.

In another study it was shown that fresh T cell lines expressing TCR V86-7, 8, and 17 or TCR V812 could be infected similarly with HIV but, after addition of antigen presenting cells, TCR V812 expressing cells had an approximately 100-fold higher HIV titre than the other three, suggesting a superantigen effect in HIV amplification.68 More needs to be done to show convincingly that HIV encodes a superantigen. If it does, it opens new strategies for vaccination and would make the MMTV system a model of choice for new vaccination studies directed at the superantigen effects.

In another study it was clearly shown that the rabies virus encodes a superantigen in its nuclear protein.70 Recombinant protein showed strong binding to MHC class II.

Figure 3 Life cycle of mouse mammary tumour virus. TCR=T cell receptor.

Infection of babies through mothers' milk

Infection of Peyer's patch lymphocytes, amplification of infected B cells through helper T cells expressing superantigen reactive TCR, induction of T cell energy

Infection of mammary gland

Mammary tumours after integration (by chance) close to proto-oncogenes

During the last year two reports suggested that HIV may encode a superantigen. The first analysed the expression of mRNA of the different TCR V8 elements in the peripheral blood of patients at late stages of AIDS. Several TCR V8 elements were found to be reduced strongly in patients with late stage disease, after the drop in the CD4+ T cell population. A semiquantitative polymerase chain reaction was used to measure mRNA expression in unseparated blood isolates. Analyses on purified CD4+ T cell populations are required to consider this question more directly as, possibly, the V8 elements which were reduced are underrepresented in the CD8+ T cell population.

In another study it was shown that fresh T cell lines expressing TCR V86-7, 8, and 17 or TCR V812 could be infected similarly with HIV but, after addition of antigen presenting cells, TCR V812 expressing cells had an approximately 100-fold higher HIV titre than the other three, suggesting a superantigen effect in HIV amplification. More needs to be done to show convincingly that HIV encodes a superantigen. If it does, it opens new strategies for vaccination and would make the MMTV system a model of choice for new vaccination studies directed at the superantigen effects.

In another study it was clearly shown that the rabies virus encodes a superantigen in its nuclear protein. Recombinant protein showed strong binding to MHC class II.
molecules and stimulated T cells expressing Vβ12 in humans and Vβ6 (the closest murine homologue) in mice. It will be interesting to see the effect of this superantigen on the efficiency of infection with rabies virus. Once this virus reaches the nerve cells it is no longer accessible to the immune system. In addition, it will be interesting to see if and how this superantigen plays a part in the vaccines used to protect against rabies infection. The results of these experiments will potentially give insights into the role of superantigens in vaccination.

Roles of superantigens in autoimmunity?

It is well known that normal subjects have some autoreactive T and B cells in their circulation. Polyclonal activation of B cells induces production of autoantibodies, and autoreactive CD4+ T cells can easily be isolated after stimulation in vitro with superantigens. The overall tolerance mechanisms can maintain a healthy equilibrium between the presence of autoreactive cells and the prevention of their predominance. Several points in the above discussion make it likely that superantigens may play a part in the induction of autoimmune diseases: (a) superantigens can induce polyclonal antibody responses; (b) superantigens can activate T cells with many different fine specificities, possibly including autoreactive T cells.

Mimicry by microbes has been proposed previously for a trigger of autoimmune reactions. In this hypothesis a sequence with similarity to host sequences is expressed by the microbe. A strong immune reaction to the invading microorganism leads to the breaking of tolerance to an autoantigen. Superantigens do not even have to express such a cross reactive epitope. By activation of a substantial proportion of the host immune cells expressing millions of different antigen specificities, several autoreactive cells might be activated (fig 5). It is not clear at present what happens to these cells when they encounter an autoantigen after superantigen activation. In experimental allergic encephalomyelitis, a model disease for human multiple sclerosis, few TCR molecules are found on the autoreactive T cells. Most share expression of TCR VB8. The bacterial superantigen SEB activates all the VB8 bearing T cells. Preliminary experiments indicate that SEB induces relapses of experimental allergic encephalomyelitis in mice, clearly suggesting the possibility of a role in classical antigen responses by potentially anergised cells (Steinman L A, personal communication). Most likely it depends on the cell type which presents the autoantigen after the superantigen encounter.

Another elegant experiment gives support for both the original mimicry as well as the superantigen hypothesis in the induction of autoimmunity. Mice were generated which bear two types of transgene. One
transgene determines the expression of an epitope for cytotoxic T cells exclusively on the pancreatic β cells, the targets of autoimmune destruction in insulin dependent diabetes mellitus. The antigen is the glycoprotein of the leucocytic choriomeningitis virus. The other transgene controls the expression of the TCR α and β chains isolated from a cytotoxic T cell specific for a peptide of this glycoprotein. Mice expressing both transgenes are non-diabetic and remain normal. Infection with a control leucocytic choriomeningitis virus which does not bear the T cell epitope does not induce diabetes, whereas infection with the leucocytic choriomeningitis virus expressing the T cell epitope induces diabetes within a few days.

Several recent studies have begun to consider questions about the role of superantigens in autoimmunity. In rheumatoid arthritis, again using semiquantitative PCR, an overrepresentation in the rheumatoid lesions of a particular TCR Vβ chain has been found, with reduced representation in the periphery.129 These findings were made using semiquantitative PCR and have to be confirmed by more quantitative methods. As soon as the necessary monoclonal antibodies are available, such analyses can be repeated on a large number of patients. In another autoimmune disease, Kawasaki disease, a high percentage of T cells expressing Vβ2 has been found in the peripheral blood of patients.82 Kawasaki disease is an acute multisystem vasculitis affecting young children. It is often found in Japanese patients. *Mycoplasma arthritidis* antigens, which have not been biochemically characterised, might yet be involved in the induction of polyarthritis in mice.51 130 148 149 Other candidates are *yersinia* superantigens and streptococcal antigens.55 83-85 145-151 Reiter’s disease is a reactive arthritis, a term used for arthritis developing after infection. Candidate infectious agents causing reactive arthritis in humans are *yersinia*, *shigella*, *salmonella*, and others.131-133 An involvement of superantigens or classical mimicry in autoimmunity would be compatible as well with geographical variations in the prevalence of autoimmune diseases.

It is still too early clearly to correlate specific autoimmune diseases with specific bacterial or viral superantigens. Indeed, it is not yet clear whether superantigens are important for autoimmunity or not. So far all the correlations amount to little more than speculation. Even if microbes can be clearly linked to the induction of autoimmune diseases, mechanisms other than superantigens are likely to contribute. The near future will tell what their role is in the known autoimmune diseases. Whatever the outcome of these studies, pathogens compensate for the morbidity they inflict by providing us with highly valuable tools for dissecting the immune system and perhaps will give us insight into the cause of some forms of autoimmunity and its prevention.

HAO was supported by a START fellowship of the Swiss National Science Foundation.

---


Frase J D. High-affinity binding of staphylococcal enterotoxins A and B to HLA-DR. Nature 1989; 342: 221-3.


Herrmann T, Mariani L J, Romero P, Fleischer B, MacDonald H R. Activation of MHC class I-restricted CD8+ CTL by microbial T cell mitogens. Dependence


